We’re Hiring: Communications Director

Job Title: Communications Director, Canadian Drug Policy Coalition

Reporting To: Executive Director 

Application Deadline: May 5, 2024, 11:59PM Pacific  

Desired Start Date: Late June, 2024 

Location: This position is open to applications from across Canada, and CDPC staff work largely remotely. CDPC offices are located on unceded xʷməθkʷəy̓əm (Musqueam), Sḵwx̱wú7mesh (Squamish), and Sel̓íl̓witulh (Tsleil-Waututh) territory at Simon Fraser University’s Harbour Centre campus in downtown Vancouver, British Columbia. This position requires that the successful candidate be located within convenient access to a major airport and have adequate and consistent access to high-speed internet and mobile networks.  

Hours and Travel: Work takes place during regular business hours, with occasional time and possible travel within Canada required on evenings and weekends for events. CDPC staff currently live and work in a range of different time zones. Staff are supported to plan their work hours to best reflect their local time zone and workflow, provided this allows for collaboration with colleagues. Tracking and responding to media requests and emergent issues may occasionally require availability outside of regular hours. 

Compensation: The annual salary range for this position is $80,000 to $85,000, commensurate with skills and experience. 

ABOUT US 

The Canadian Drug Policy Coalition (CDPC) is a national organization that promotes drug policies based on principles of public health and human rights.  

CDPC engages in policy analysis, advocacy, public education and dialogue, and movement building within regional, national and international arenas with a goal of informing, educating and mobilizing citizens to become engaged in global drug policy reform. CDPC is a partner project of the Faculty of Health Sciences at Simon Fraser University in British Columbia.  

The CDPC’s Communications Director leads efforts to maximize the strategic impact and reach of CDPC’s work through communications: increasing public awareness of and education around a public health and human rights-based approach to drug policy; mobilizing existing CDPC audiences and expanding to engage new audiences. This position leads all aspects of CDPC’s communications, supervises the Digital Communications Specialist, collaborates with all CDPC staff, participates in the organizational oversight and support team, and reports to the Executive Director.  

The Canadian Drug Policy Coalition values equity, diversity, justice and inclusion and is focused on enriching our commitment to and application of these principles. We encourage applicants from a range of communities, experiences and backgrounds including Indigeneity, race, drug use, ability, sexuality, gender, and those affected by the criminalization of drug use and/or sex work.  (Disclosure of these identities and experiences is welcome but not expected/required; there will be opportunities to demonstrate skills and knowledge during the recruitment process.) We strongly encourage you to apply if you have a passion for CDPC’s mission and meet the core required qualities and attributes below. 

JOB RESPONSIBILITIES 

Shared responsibility to further Representation, Equity, Diversity 

Promote improvements to representation, equity and diversity in all aspects of job responsibilities 

Commit to ongoing learning, consultation, reflection and action to address the colonial, racist and classist roots upon which drug policy was formed and continues to operate 

Contribute to learning and implementation of intersectional anti-racist practice in the development of CDPC policy, education, operations, mobilization and communication activities 

Communications Strategy and Planning 

Develop, manage, execute and evaluate CDPC’s communications strategy 

Oversee and deliver communications learning and development with CDPC staff 

Manage CDPC contributions to communications learning and development with broader drug policy network and cross-sector partners 

Develop, refine and update organizational and issue-based key messaging with the input and support of CDPC staff 

Content Creation and Strategy Implementation 

Cultivate and support CDPC spokespeople, training staff on communications strategies, key messages, and use of materials 

Develop and implement CDPC earned media strategy, with the support and participation of CDPC staff 

Coordinate press conferences 

Respond to media requests, maintain positive working relationships with media 

Draft, edit and disseminate press releases  

Work with CDPC staff to pitch media stories  

Support CDPC staff to write and pitch op-eds 

Develop and maintain relationships with key media organizations and people across Canada 

Track and catalogue media coverage and assess impact and learnings from coverage 

Update and maintain media contact database 

Support Digital Communications Specialist to draft and implement email engagement strategy 

Engage existing list, mobilize learning and action within list 

Grow and diversify CDPC email list  

Support Digital Communications Specialist to draft and implement social media strategy 

Support Digital Communications Specialist and CDPC staff to create social media content 

Support executive director and CDPC staff to draft and implement strategies for donation-based fundraising 

Work with digital communications specialist to integrate fundraising into communications workflows, processes and systems 

Oversee production of communications materials, including print materials, blog and digital content, issue guides and organizational statements 

Strategic Leadership and Management 

Manage and mentor communications staff  

Digital Communications Specialist  

Communications-related external contractor relationships  

Oversee communications budget 

As part of the organizational oversight and support team, collaborate with the Executive Director to support CDPC’s overall organizational management, human resources, and staff wellness  

Act as the strategic communications focal point for key CDPC programs, campaigns and teams 

Coordinate closely with the Executive Director and other staff to support CDPC’s fundraising efforts 

Other 

Support communications with CDPC coalition and collaborators, and recommend system improvements as needed 

Participate in organization or project-based evaluation and modify strategies and activities accordingly  

Other duties as required 

KNOWLEDGE, SKILLS AND EXPERIENCE 

We strongly encourage you to apply if you have a passion for CDPC’s mission and meet the below core requirements: 

Minimum 3 years’ experience in communications leadership, designing and implementing communications strategies, digital and social media campaigns, audience targeting, and narrative development best practices for organizations, projects and campaigns  

Post-secondary training in communications, journalism or a related field, or the equivalent combination of professional experience 

Fluency in written and spoken English 

Highly skilled in written communication and editing, including adapting complex content to create accessible communications for diverse audiences 

Demonstrated ability to lead a team, effectively supervise and manage staff, and delegate work  

Strong attention to detail, organizational and prioritization skills, with the demonstrated ability to manage multiple competing priorities under time pressures  

Demonstrated experience navigating earned media landscape: successfully crafting press releases, pitching and landing media stories, writing and placing op-eds 

Strong news sense and ability to identify and react to major developments in the drug policy field 

Experience implementing best practices in digital supporter engagement, including email list-building, list segmentation and mobilization 

Proficient with a range of communications-related technology, which may include WordPress, HTML/CSS, Microsoft Office Suite, Adobe Creative Suite, Canva, email newsletter management, supporter database/CRM (we use Nationbuilder currently) 

Understanding of key elements of drug policy in Canada, or willingness and aptitude to learn quickly  

Commitment and aptitude to grounding work in principles of equity and intersectional anti-racism and decolonialism, and ethically sharing stories and personal narratives on complex subjects 

The following are considered additional assets (we do not expect any one candidate to have all of these): 

French language fluency  

Graphic design skills, including experience with Photoshop and InDesign  

Demonstrated ability to draft engaging and creative social media content and campaigns through graphics, videos, TikTok scripts etc. 

Experience designing and implementing fundraising campaigns 

APPLICATION PROCESS 

The application deadline is Sunday, May 5, 2024 at 11:59pm Pacific Time. Please send a short cover letter and resume as a single PDF to cdpc@sfu.ca, using the naming convention CommsDirector_FirstnameLastname.pdf. We anticipate conducting interviews in May.  

The hiring team may adapt the process as needed to understand candidates’ potential to succeed in this role. We currently anticipate this selection process will include: 

Shortlisting, likely involving a short phone screening call 

One or two interviews, which will be via video call 

Reference checks (please be prepared to provide the names and contact info for three employment references who can speak to your experience and potential for this role) 

If you have any questions about the recruitment process, please contact cdpc@sfu.ca. 

Early applications are encouraged and appreciated.

The post We’re Hiring: Communications Director appeared first on Canadian Drug Policy Coalition.

Financial Transparency and Efficiency of the Prescription Drug User Fee Act, Biosimilar User Fee Act, and Generic Drug User Fee Amendments; Public Meeting; Request for Comments

The Food and Drug Administration (FDA or the Agency) is announcing the following public meeting entitled “Financial Transparency and Efficiency of the Prescription Drug User Fee Act, Biosimilar User Fee Act, and Generic Drug User Fee Amendments.” The topic to be discussed is the financial transparency and efficiency of the Prescription Drug User Fee Act, Biosimilar User Fee Act, and Generic Drug User Fee Amendments.

Determination That NALFON (Fenoprofen Calcium) Oral Capsules, Equivalent to 300 Milligram Base, and Other Drug Products Were Not Withdrawn From Sale for Reasons of Safety or Effectiveness

The Food and Drug Administration (FDA or Agency) has determined that the drug products listed in this document were not withdrawn from sale for reasons of safety or effectiveness. This determination means that FDA will not begin procedures to withdraw approval of abbreviated new drug applications (ANDAs) that refer to these drug products, and it will allow FDA to continue to approve ANDAs that refer to the products as long as they meet relevant legal and regulatory requirements.

21st Century Cures Act: Annual Compilation of Notices of Updates From the Susceptibility Test Interpretive Criteria Web Page; Request for Comments

The Food and Drug Administration (FDA, the Agency, or we) is announcing the availability of the Agency’s annual compilation of notices of updates to the Agency’s Susceptibility Test Interpretive Criteria web page. The Agency established the Susceptibility Test Interpretive Criteria web page on December 13, 2017, and since establishment has provided updates to both the format of the web pages and the susceptibility test interpretive criteria identified and recognized by FDA on the web pages. FDA is publishing this notice in accordance with procedures established by the 21st Century Cures Act (Cures Act).

Joint Statement of the 11th ASEAN Finance Ministers’ and Central Bank Governors’ Meeting (AFMGM)

The 11th ASEAN Finance Ministers’ and Central Bank Governors’ Meeting (AFMGM) was convened under the co-chairmanship of H.E. Mr. Santiphab Phomvihane, Finance Minister and H.E. Mr. Bounleua Sinxayvoravong, Governor of the Bank of the Lao PDR. ASEAN Chair 2024 Priorities The Meeting welcomed Lao PDR’s … Continue reading Joint Statement of the 11th ASEAN Finance Ministers’ and Central Bank Governors’ Meeting (AFMGM)

Request for Nominations for Voting Members for the Patient Engagement Advisory Committee

The Food and Drug Administration (FDA or the Agency) is requesting nominations for voting members, excluding consumer and industry representatives, to serve on the Patient Engagement Advisory Committee (the Committee) in the Center for Devices and Radiological Health. Nominations will be accepted for upcoming vacancies effective with this notice. FDA seeks to include the views of members of all gender groups, members of all racial and ethnic groups, and individuals with and without disabilities on its advisory committees and, therefore, encourages nominations of appropriately qualified candidates from these groups.

Request for Nominations on Device Good Manufacturing Practice Advisory Committee

The Food and Drug Administration (FDA or Agency) is requesting that any industry organization interested in participating in the selection of a nonvoting industry representative to serve on the Device Good Manufacturing Practice Advisory Committee (DGMPAC) in the Center for Devices and Radiological Health notify FDA in writing. FDA is also requesting nominations for a nonvoting industry representative to fill an upcoming vacancy on DGMPAC. A nominee may either be self-nominated or nominated by an organization to serve as a nonvoting industry representative. Nominations will be accepted for an upcoming vacancy effective with this notice.

Determination That GLUCOTROL (Glipizide) Tablets, 5 Milligrams and 10 Milligrams, Were Not Withdrawn From Sale for Reasons of Safety or Effectiveness

The Food and Drug Administration (FDA or Agency) has determined that GLUCOTROL (glipizide) tablets, 5 milligrams (mg) and 10 mg, were not withdrawn from sale for reasons of safety or effectiveness. This determination means that FDA will not begin procedures to withdraw approval of abbreviated new drug applications (ANDAs) that refer to these drug products, and it will allow FDA to continue to approve ANDAs that refer to these products as long as they meet relevant legal and regulatory requirements.